Necrosis News and Research

RSS

Adeno-associated virus type 2 kills triple-negative breast cancer cells in mice

A virus not known to cause disease kills triple-negative breast cancer cells and killed tumors grown from these cells in mice, according to Penn State College of Medicine researchers. Understanding how the virus kills cancer may lead to new treatments for breast cancer.

24 Jun 2014

Tumor necrosis factor alpha antagonists not linked with increased risk of cancer

In a study that included more than 56,000 patients with inflammatory bowel disease, use of a popular class of medications known as tumor necrosis factor alpha antagonists was not associated with an increased risk of cancer over a median follow-up of 3.7 years, although an increased risk of malignancy in the long term, or with increasing number of doses, cannot be excluded, according to a study in the June 18 issue of JAMA.

18 Jun 2014

One-third of PsA patients not receiving adalimumab doses to achieve optimal clinical benefit

Data presented today at the European League Against Rheumatism Annual Congress showed that a significant number of patients with psoriatic arthritis (PsA) were not receiving doses of the tumour necrosis factor-alpha (TNFα) inhibitor adalimumab necessary to achieve optimal clinical benefit.

12 Jun 2014

Polyarticular juvenile idiopathic arthritis (PJIA): an interview with Dr. Kramer, VP, Immunology and Infectious Diseases Medical Unit, Genentech

Polyarticular Juvenile Idiopathic Arthritis (PJIA) is a type of Juvenile Idiopathic Arthritis (JIA), a group of Rheumatoid Arthritis (RA) diseases that manifests in multiple ways in children.

3 Jun 2014

EC approves Takeda's Entyvio for treatment of adults with ulcerative colitis, Crohn’s disease

Takeda Pharmaceutical Company Limited and its wholly-owned subsidiary, Takeda Pharmaceuticals International GmbH, today announced that the European Commission has granted Marketing Authorisation for Entyvio (vedolizumab), a gut-selective humanized monoclonal antibody, and the first and only biologic therapy to be approved simultaneously for the treatment of adults with moderately to severely active ulcerative colitis (UC) and adults with moderately to severely active Crohn’s disease (CD) who have had an inadequate response with, lost response to, or were intolerant to either conventional therapy or a tumor necrosis factor-alpha (TNFα) antagonist.

28 May 2014

Edison Pharmaceuticals' EPI-743 granted orphan designation for Leigh syndrome in Japan

Edison Pharmaceuticals has announced that the Japanese Ministry of Health, Labor and Welfare (MHLW) has granted Orphan Designation to EPI-743 for the treatment of Leigh syndrome.

21 May 2014

FDA approves Takeda's Entyvio for severe active ulcerative colitis and Crohn's disease

Takeda Pharmaceutical Company Limited and its wholly-owned subsidiary, Takeda Pharmaceuticals U.S.A., Inc., has announced that the United States (U.S.) Food and Drug Administration (FDA) simultaneously approved a new biologic therapy, Entyvio™ (vedolizumab), for the treatment of adults with moderately to severely active ulcerative colitis (UC) and Crohn's disease (CD).

21 May 2014

Innate immune response may warn of chronic multisite musculoskeletal pain

An enhanced innate immune response may be an indicator of the onset or prolongation of chronic, multisite musculoskeletal pain, cross-sectional study findings suggest.

19 May 2014

Zenalux, RPCI collaborate to enhance Zenascope system to detect oral cancers at an early stage

Zenalux Biomedical, Inc., a leader in biophotonic diagnostics, is working with Roswell Park Cancer Institute to further enhance its flagship Zenascope™ product by adding a high-resolution camera to the system.

25 Apr 2014

Surgery promising for non-metastatic RCC with thrombus

Almost half of patients with non-metastatic renal cell carcinoma who have tumour thrombus above the hepatic veins will survive for 5 years after surgery, indicate study results published in The Journal of Urology.

22 Apr 2014

New data focuses on different approaches to improve diagnosis and treatment of HCC

Epidemiological, genetic and clinical data presented today at the International Liver CongressTM 2014 are collectively focussed on different approaches designed to improve the diagnosis, staging and treatment of hepatocellular carcinoma (HCC).

15 Apr 2014

Study: Ginsenoside Rb1 attenuates neuronal damage following cerebral ischemia

Activated microglia-mediated inflammation promotes neuronal damage under cerebral hypoxic-ischemic conditions, so it is likely that inhibiting hypoxia-induced activation of microglia will alleviate neuronal damage.

7 Apr 2014

Study: Dab2 can exhibit neuroprotective effects in Alzheimer's by regulating TGF-β1/SMAD signaling

Transforming growth factor-beta (TGF-β) type II receptor (TβRII) levels are extremely low in the brain tissue of patients with Alzheimer's disease.

27 Mar 2014

Systemic stem cell therapy reduces malignant mesothelioma growth

Systemic delivery of stem cells expressing an apoptosis-inducing protein can successfully incorporate into malignant pleural mesothelioma cells and subsequently induce their death, according to preclinical study findings.

19 Mar 2014

Rheumatoid arthritis and switching TNFis: an interview with Professor Paul Emery, University of Leeds

Tumor necrosis factor inhibitors (TNFis) are used to treat inflammatory conditions, such as RA. These agents work by blocking TNF, an important mediator of inflammation in RA, in order to help reduce inflammation and stop disease progression.

12 Mar 2014

Women are most likely to experience serious pain following knee replacement than men

Middle-aged women with rheumatoid arthritis or arthritis resulting from an injury are among the patients most likely to experience serious pain following a knee replacement, researchers from Hospital for Special Surgery (HSS) in New York have found.

12 Mar 2014

Inflammation and stress combine in bipolar and schizophrenia subtypes

Researchers have found that some individuals with bipolar disorder or schizophrenia have combined stress response and immune dysfunctions.

6 Mar 2014

FDA approves Iroko Pharmaceuticals’ TIVORBEX capsules

Iroko Pharmaceuticals, LLC, a global specialty pharmaceutical company dedicated to advancing the science of analgesia, today announced that the U.S. Food and Drug Administration (FDA) has approved TIVORBEX™ (indomethacin) capsules, a nonsteroidal anti-inflammatory drug (NSAID), at 20 mg and 40 mg doses for the treatment of mild to moderate acute pain in adults.

25 Feb 2014

Infliximab drug shows promising results in treating children with Kawasaki Disease

Kawasaki Disease (KD) is a severe childhood disease that many parents, even some doctors, mistake for an inconsequential viral infection. If not diagnosed or treated in time, it can lead to irreversible heart damage.

25 Feb 2014

Ulcerative colitis patients not satisfied with current treatments according to new study

Patients with a serious type of inflammatory bowel disease, ulcerative colitis, are not satisfied with their current treatments and the majority do not have their disease under control, according to new research released today at the 9th Congress of the European Crohn’s and Colitis Organisation (ECCO) in Copenhagen. The majority (87.2 per cent) of the 250 patients with moderate to severe ulcerative colitis who were being treated with standard therapies failed to achieve control of their disease – defined either as going into remission or not having needed to use corticosteroid medications in the previous two months.1

21 Feb 2014

Necrosis News and Research

Adeno-associated virus type 2 kills triple-negative breast cancer cells in mice

Tumor necrosis factor alpha antagonists not linked with increased risk of cancer

One-third of PsA patients not receiving adalimumab doses to achieve optimal clinical benefit

Polyarticular juvenile idiopathic arthritis (PJIA): an interview with Dr. Kramer, VP, Immunology and Infectious Diseases Medical Unit, Genentech

EC approves Takeda's Entyvio for treatment of adults with ulcerative colitis, Crohn’s disease

Edison Pharmaceuticals' EPI-743 granted orphan designation for Leigh syndrome in Japan

FDA approves Takeda's Entyvio for severe active ulcerative colitis and Crohn's disease

Innate immune response may warn of chronic multisite musculoskeletal pain

Zenalux, RPCI collaborate to enhance Zenascope system to detect oral cancers at an early stage

Surgery promising for non-metastatic RCC with thrombus

New data focuses on different approaches to improve diagnosis and treatment of HCC

Study: Ginsenoside Rb1 attenuates neuronal damage following cerebral ischemia

Study: Dab2 can exhibit neuroprotective effects in Alzheimer's by regulating TGF-β1/SMAD signaling

Systemic stem cell therapy reduces malignant mesothelioma growth

Rheumatoid arthritis and switching TNFis: an interview with Professor Paul Emery, University of Leeds

Women are most likely to experience serious pain following knee replacement than men

Inflammation and stress combine in bipolar and schizophrenia subtypes

FDA approves Iroko Pharmaceuticals’ TIVORBEX capsules

Infliximab drug shows promising results in treating children with Kawasaki Disease

Ulcerative colitis patients not satisfied with current treatments according to new study

Achieving and maintaining ISO 27001 and BS 10012 certifications

Expanding research and clinical options for children with cancer

Examining how pain could play a direct protective role in the gut

Latest News